Nofazinlimab is a monoclonal antibody commercialized by CStone Pharmaceuticals, with a leading Phase III program in Hepatocellular Carcinoma. According to Globaldata, it is involved in 4 clinical trials, of which 3 were completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Nofazinlimab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Nofazinlimab is expected to reach an annual total of $39 mn by 2037 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Nofazinlimab is under development for the treatment of solid tumors including soft tissue sarcoma, LPS (dedifferentiated or other high grade liposarcoma), malignant pleural mesothelioma (MPM), bladder cancer, advanced hepatocellular carcinoma, merkel-cell carcinoma, colon cancer, melanoma, gastrointestinal stromal tumour (GIST), gastric cancer, oesophageal carcinoma, small-cell lung cancer (SCLC), large-cell lung cancer (LCLC), lymphoma, head and neck squamous cell carcinoma (HNSCC) or cutaneous squamous cell carcinoma (cuSCC) or tumors with microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR), laryngeal squamous cell carcinoma, uterine leiomyosarcoma, esophageal squamous cell carcinoma and gastric adenocarcinoma. It is administered through the intravenous route of administration. The drug candidate is a humanized IgG4 anti-PD-1 monoclonal antibody developed based on hybridoma technology platform. It acts by targeting programmed cell death 1 (PD1).
CStone Pharmaceuticals Overview
CStone Pharmaceuticals is a biopharmaceutical company. It develops and commercializes immuno-oncology and precision medicine to address the unmet medical needs of cancer patients. The company’s pipeline product portfolio includes Ivosidenib (CS3010) for the treatment of acute myeloid leukemia (AML); CS1001 to treat solid tumors; Avapritinib (CS3007) for the treatment of liver diseases; CS1002, CS1003, CS3006, CS3003, CS3002 to treat solid tumors. CStone Pharmaceuticals operates clinical research institutions for developing anti-cancer drugs. The company has partnerships with Agios Inc, Blueprint Medicines Corp, and WuXi Biologics. CStone Pharmaceuticals is headquartered in Shanghai, China.
The company reported revenues of (Renminbi) CNY243.7 million for the fiscal year ended December 2021 (FY2021), a decrease of 76.5% over FY2020. The operating loss of the company was CNY1,917.9 million in FY2021, compared to an operating loss of CNY1,219.7 million in FY2020. The net loss of the company was CNY1,920.1 million in FY2021, compared to a net loss of CNY1,221 million in FY2020.
For a complete picture of Nofazinlimab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.